1. Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

   • Yousef Al-Saleh
   • Shaun Sabico
   • Nasser M. Al-Daghri

   Guidelines Open access 13 May 2021 Pages: 2115 - 2132

   

2. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)

   • Sanjay Kalra
   • Saptarshi Bhattacharya
   • Nitin Kapoor

   Review Open access 15 July 2021 Pages: 2133 - 2147

3. Differential Cost-Sharing Undermines Treatment Adherence to Combination Therapy: Evidence from Diabetes Treatment

   • David R. Nelson
   • Pamela Heaton
   • Jieling Chen

   Original Research Open access 01 July 2021 Pages: 2149 - 2164

   

4. Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study

   • Masato Odawara
   • Sumiko Aoi
   • Kosuke Iwasaki

   Original Research Open access 04 July 2021 Pages: 2165 - 2177

   

5. Analysis Estimating the Potential Cost Impact of Utilizing Flash Glucose Monitoring with Optional Alarms in Swedish Adults with Diabetes with Impaired Awareness of Hypoglycaemia, Using Intensive Insulin

   • Deirdre B. Blissett
   • Stig Attvall
   • Richard A. Hellmund

   Original Research Open access 07 July 2021 Pages: 2179 - 2193

   

6. The Impact of Different Insulin-Related Measures on the Risk of Prediabetes Among the Chinese Han Population

   • Huibiao Quan
   • Tuanyu Fang
   • Zhiguang Zhou

   Original Research Open access 08 July 2021 Pages: 2195 - 2206

   

7. The Impact of COVID-19 Lockdown on Metabolic Control and Access to Healthcare in People with Diabetes: the CONFI-DIAB Cross-Sectional Study

   • Lisa Ludwig
   • Nicolas Scheyer
   • Bruno Guerci

   Original Research Open access 09 July 2021 Pages: 2207 - 2221

8. Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States

   • Kristina S. Boye
   • Elif Tokar Erdemir
   • Lida Etemad

   Original Research Open access 18 July 2021 Pages: 2223 - 2239

   

9. Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

   • Yu Hoshika
   • Yoshiaki Kubota
   • Wataru Shimizu

   Brief Report Open access 08 July 2021 Pages: 2241 - 2248

   

10. SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review

    • Andrej Janež
    • Paola Fioretto

    Brief Report Open access 09 July 2021 Pages: 2249 - 2261

    

11. Correction to: Cost Analysis of FreeStyle Libre^® 2 System in Type 2 Diabetes Mellitus Population

    • Itziar Oyagüez
    • Fernando Gómez-Peralta
    • Antonio Pérez

    Correction Open access 09 July 2021 Pages: 2263 - 2264

12. Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

    • Yousef Al-Saleh
    • Shaun Sabico
    • Nasser M. Al-Daghri

    Correction Open access 23 July 2021 Pages: 2265 - 2266